Editas Medicine Announces First Quarter 2020 Results and Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Editas Medicine (EDIT) Tops Q1 EPS by 8c
May 7, 2020 7:48 AM EDTEditas Medicine (NASDAQ: EDIT) reported Q1 EPS of ($0.69), $0.08 better than the analyst estimate of ($0.77).
The COVID-19 pandemic has given rise to unprecedented circumstances for Editas and the broader life sciences community, said Cynthia Collins, Chief Executive Officer of Editas Medicine. Our top priority is safety and we have implemented measures to ensure that safety comes first while mitigating the disruption to our... More
